HUP0204162A2 - Spiro[2H-1-benzopirán-2,4'-piperidin]-származékok, mint glicin transzport inhibitorok és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Spiro[2H-1-benzopirán-2,4'-piperidin]-származékok, mint glicin transzport inhibitorok és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0204162A2
HUP0204162A2 HU0204162A HUP0204162A HUP0204162A2 HU P0204162 A2 HUP0204162 A2 HU P0204162A2 HU 0204162 A HU0204162 A HU 0204162A HU P0204162 A HUP0204162 A HU P0204162A HU P0204162 A2 HUP0204162 A2 HU P0204162A2
Authority
HU
Hungary
Prior art keywords
optionally
group
derivatives
alkyl
alkyl group
Prior art date
Application number
HU0204162A
Other languages
English (en)
Inventor
Samuel George Gibson
David John Miller
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of HUP0204162A2 publication Critical patent/HUP0204162A2/hu
Publication of HUP0204162A3 publication Critical patent/HUP0204162A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány tárgyát az (I) általános képletű spiro[2H-1-benzopirán-2,4'-piperidin]-származékok és gyógyászati szempontból elfogadhatósóik képezik - a képletben a szaggatott vonal adott esetben jelenlévővegyértékkötést jelöl; Y 1-4 helyettesítőt jelöl, amelyek jelentéseegymástól függetlenül hidrogénatom, halogénatom, adott esetben egyvagy több halogénatommal helyettesített alkilcsoport, adott esetbenegy vagy több halogénatommal vagy cikloalkilcsoporttal helyettesítettalkiloxicsoport, alkeniloxi-, alkiniloxi-, cikloalkiloxi-, ariloxi-,arilalkiloxi-, heteroariloxi-, heteroarilalkiloxi-csoport, -SR3, -NR3R4, -OSO2R5 és -NR3SO2R4; két Y helyettesítő együtt -O-(CH2)n O-vagy -O-(CF2)n-O-csoportot képezhet, ahol n értéke 1 vagy 2; vagy Yjelentése lehet összeolvadt arilcsoport; X 1-3 helyettesítőt jelöl,amelyek jelentése egymástól függetlenül hidrogénatom, halogénatom,hidroxilcsoport, alkoxicsoport, -SR3, -NR3SO2R4 és adott esetbenhalogénatommal helyettesített alkilcsoport; R1 jelentése hidrogénatom,alkil- vagy arilcsoport; R2, R3 és R4 jelentése egymástól függetlenülhidrogénatom vagy alkilcsoport; R5 jelentése adott esetben egy vagytöbb halogénatommal helyettesített alkilcsoport vagy adott esetbenalkilcsoporttal helyettesített arilcsoport -. A találmány tárgyátképezik még a fenti származékokat tartalmazó gyógyászati készítmények,valamint a fenti vegyületek alkalmazása a központi idegrendszerrendellenességeinek kezelésére vagy megelőzésére szolgáló gyógyászatikészítmények előállítására, és a fenti vegyületek maguk gyógyászatialkalmazásra. Ó
HU0204162A 1999-11-17 2000-11-13 Spiro(2h-1-benzopyran-2,4'-piperidine) derivatives as glycine transport inhibitors and pharmaceutical compositions containing them HUP0204162A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99309137 1999-11-17
PCT/EP2000/011351 WO2001036423A1 (en) 1999-11-17 2000-11-13 Spiro(2h-1-benzopyran-2,4'-piperidine) derivates as glycine transport inhibitors

Publications (2)

Publication Number Publication Date
HUP0204162A2 true HUP0204162A2 (hu) 2003-04-28
HUP0204162A3 HUP0204162A3 (en) 2006-01-30

Family

ID=8241739

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204162A HUP0204162A3 (en) 1999-11-17 2000-11-13 Spiro(2h-1-benzopyran-2,4'-piperidine) derivatives as glycine transport inhibitors and pharmaceutical compositions containing them

Country Status (29)

Country Link
US (2) US6645973B1 (hu)
EP (1) EP1232160B1 (hu)
JP (1) JP4825386B2 (hu)
KR (1) KR100776226B1 (hu)
CN (1) CN1199974C (hu)
AR (1) AR026487A1 (hu)
AT (1) ATE398622T1 (hu)
AU (1) AU779518B2 (hu)
BR (1) BR0015586A (hu)
CA (1) CA2389491C (hu)
CO (1) CO5261618A1 (hu)
CY (1) CY1108339T1 (hu)
CZ (1) CZ293920B6 (hu)
DE (1) DE60039247D1 (hu)
DK (1) DK1232160T3 (hu)
ES (1) ES2307536T3 (hu)
HK (1) HK1047282B (hu)
HU (1) HUP0204162A3 (hu)
IL (2) IL149286A0 (hu)
NO (1) NO327743B1 (hu)
NZ (1) NZ518671A (hu)
PE (1) PE20010750A1 (hu)
PL (1) PL206071B1 (hu)
PT (1) PT1232160E (hu)
RU (1) RU2250211C2 (hu)
SK (1) SK287040B6 (hu)
TW (1) TWI243173B (hu)
WO (1) WO2001036423A1 (hu)
ZA (1) ZA200203320B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI243173B (en) * 1999-11-17 2005-11-11 Akzo Nobel Nv Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives
FR2842804B1 (fr) * 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
BRPI0415165A (pt) * 2003-10-01 2007-01-09 Adolor Corp composto heterocìclico espirocìclico, composição farmacêutica, método para ligar receptores opióides, métodos para prevenir ou tratar dor, disfunção gastrointestinal, um distúrbio do trato urogenital, um distúrbio imunomodulatório, um distúrbio inflamatório, um distúrbio de função respiratória, ansiedade, distúrbio do humor, um distúrbio relacionado a estresse, distúrbio do sistema nervoso simpático, tosse, e um distúrbio motor, método para tratar uma lesão traumática ao sistema nervoso central, métodos para prevenir ou tratar acidente vascular, arritmia cardìaca, glaucoma, e disfunção sexual, métodos para tratar uma condição selecionada do grupo consistindo de choque, edema cerebral, isquemia cerebral, déficit cerebral após cirurgia cardìaca (bypass) e enxerto, lupus eritematoso sistêmico, doença de hodgkin, doença de sjogren, epilepsia, e rejeição em transplantes de órgão e enxertos de pele, e para tratar dependência de substáncias, métodos para melhorar a sobrevivência de órgãos e células, e cardioproteção após infarto do miocárdio, métodos para reduzir a necessidade de anestesia, para produzir ou manter um estado anestésico, derivado radiomarcado de um composto, derivado isotopicamente marcado de um composto, composto e método de diagnóstico por imagem
CA2552914C (en) * 2004-01-08 2010-09-14 F.Hoffmann-La Roche Ag Diaza-spiropiperidine derivatives
EP1716147B1 (en) * 2004-01-08 2007-11-14 F.Hoffmann-La Roche Ag Diaza-spiropiperidine derivatives as inhibitors of glycine transporter 1 and glycine transporter 2
EP1735057B1 (en) * 2004-03-22 2015-02-25 Apkarian Technologies LLC Method and compositions for treatment of chronic neuropathic pain
CN101184749B (zh) * 2005-03-31 2012-12-05 阿得罗公司 螺环杂环衍生物及其使用方法
US7598261B2 (en) 2005-03-31 2009-10-06 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
WO2007128782A1 (en) * 2006-05-05 2007-11-15 Boehringer Ingelheim International Gmbh Spiro- (tho) benzopyran-2, 4' -piperidine-and cyclohexane derivatives as inhibitors of specific cell cycle enzymes
EP2399577A1 (en) * 2006-09-12 2011-12-28 Adolor Corporation Use of N-containing spirocompounds for the enhancement of cognitive function
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
KR100888468B1 (ko) * 2007-08-31 2009-03-11 한국화학연구원 항암활성을 갖는1'-알킬피페리딘-4'-스피로-2-6-(아미도)-2ｈ-벤조피란유도체
US20100317679A1 (en) * 2007-09-21 2010-12-16 Ligand Pharmaceuticals, Inc. Substituted aryl-fused spirocyclic amines
EP2380595A1 (en) 2010-04-19 2011-10-26 Nlife Therapeutics S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
TW201643169A (zh) * 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
US20170143681A1 (en) 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
CN116621187B (zh) * 2023-07-24 2023-09-22 江苏泓顺硅基半导体科技有限公司 一种用于高温氯化提纯石英砂的设备

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
FR2689509B1 (fr) * 1992-04-01 1994-06-03 Adir Nouveaux derives spiraniques du 3-amino chromane, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
DK78692D0 (da) * 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
IL107881A0 (en) * 1992-12-05 1994-04-12 Fisons Corp Furanone derivatives and pharmaceutical compositions containing them
AU683247B2 (en) * 1993-02-12 1997-11-06 Merck & Co., Inc. Spiro (2H-1-benzopyran-2, 4' piperidine) class III antiarrhythmics
US5484923A (en) * 1993-06-10 1996-01-16 Merck & Co., Inc. Process of making spirocycles and analogs thereof
US5439914A (en) * 1994-02-18 1995-08-08 Merck & Co., Inc. Spirocycles
GB9421003D0 (en) * 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
US5654316A (en) * 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
WO1997020552A1 (en) 1995-12-07 1997-06-12 Albert Einstein College Of Medicine Of Yeshiva University Treatment of negative and cognitive symptoms of schizophrenia with glycine and its precursors
HUP9600928A3 (en) * 1996-04-10 1999-03-29 Richter Gedeon Vegyeszet Use of spiro[2h-1-benzopyran-2,4'-piperidin]-4(3h)-one derivatives for the preparation of pharmaceutical compositions treating dementia, novel derivatives and process for their preparation
JP4403212B2 (ja) 1996-05-31 2010-01-27 エヌピーエス ファーマシューティカルズ インコーポレイテッド 神経障害および神経心理学的障害の治療のための製剤学的薬剤
SK285854B6 (sk) 1996-05-31 2007-09-06 Allelix Neuroscience Inc. Substituovaný amín, spôsoby jeho prípravy a použitie, farmaceutický prostriedok a jeho použitie
US5919653A (en) 1996-08-20 1999-07-06 Allelix Neuroscience Inc. Nucleic acids encoding a human glycine transporter
AU2030999A (en) 1998-01-09 1999-07-26 Allelix Neuroscience, Inc. Glycine transport inhibitors
TW555757B (en) 1998-07-31 2003-10-01 Akzo Nobel Nv Aminomethylcarboxylic acid derivatives
TWI243173B (en) * 1999-11-17 2005-11-11 Akzo Nobel Nv Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives
US6818649B2 (en) * 2000-04-27 2004-11-16 Basilea Pharmaceutica Ag Chromenylmethyl pyrimidinediamines as antibacterial agents

Also Published As

Publication number Publication date
IL149286A0 (en) 2002-11-10
RU2250211C2 (ru) 2005-04-20
NZ518671A (en) 2003-10-31
NO20022320L (no) 2002-05-15
CZ20021724A3 (cs) 2002-08-14
EP1232160B1 (en) 2008-06-18
HUP0204162A3 (en) 2006-01-30
PE20010750A1 (es) 2001-07-19
EP1232160A1 (en) 2002-08-21
US6645973B1 (en) 2003-11-11
PL355975A1 (en) 2004-05-31
SK8432002A3 (en) 2002-10-08
CN1390221A (zh) 2003-01-08
WO2001036423A1 (en) 2001-05-25
TWI243173B (en) 2005-11-11
CY1108339T1 (el) 2014-02-12
AR026487A1 (es) 2003-02-12
CA2389491C (en) 2010-11-02
SK287040B6 (sk) 2009-10-07
PL206071B1 (pl) 2010-06-30
JP2003527340A (ja) 2003-09-16
IL149286A (en) 2008-08-07
AU1521901A (en) 2001-05-30
ES2307536T3 (es) 2008-12-01
HK1047282B (zh) 2008-08-29
CO5261618A1 (es) 2003-03-31
ZA200203320B (en) 2003-08-27
HK1047282A1 (en) 2003-02-14
US7507824B2 (en) 2009-03-24
CA2389491A1 (en) 2001-05-25
PT1232160E (pt) 2008-09-30
KR100776226B1 (ko) 2007-11-16
CZ293920B6 (cs) 2004-08-18
BR0015586A (pt) 2002-07-09
KR20020050287A (ko) 2002-06-26
CN1199974C (zh) 2005-05-04
DE60039247D1 (de) 2008-07-31
JP4825386B2 (ja) 2011-11-30
AU779518B2 (en) 2005-01-27
NO327743B1 (no) 2009-09-14
ATE398622T1 (de) 2008-07-15
US20040029904A1 (en) 2004-02-12
DK1232160T3 (da) 2008-10-06
NO20022320D0 (no) 2002-05-15

Similar Documents

Publication Publication Date Title
HUP0204162A2 (hu) Spiro[2H-1-benzopirán-2,4'-piperidin]-származékok, mint glicin transzport inhibitorok és ezeket tartalmazó gyógyszerkészítmények
WO1993014084A3 (en) Piperidine derivatives
DE69915027D1 (de) Heteroaromatische bizyklische Verbindungen mit Antikrebswirkung
NO885352L (no) Vannloeselige camptothecin-analoger.
HUP9902471A2 (hu) Piperazin- és piperidinvegyületek, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
HUP0203142A2 (hu) Benzodiazepinszármazékok, eljárás a vegyületek előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AU4925199A (en) Quinolin-2-one derivatives useful as anticancer agents
HUP0301311A2 (hu) N-oxidok mint 4-fenil-piridin-származékok előgyógyszerei, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0003700A2 (hu) Kondenzált gyűrűs szubsztituenseket tartalmazó 2-aminopiridinek mint NOS inhibitorok
MY133474A (en) Aryl fused azapolycyclic compounds
NZ515407A (en) 4-Phenyl-pyrimidine derivatives
IL86080A0 (en) Bicyclic compounds,processes for preparation thereof and pharmaceutical composition comprising the same
IL86725A (en) 1-alkyl-n-cycloalkyl- 6-methyl-ergoline-8'- carboxamides, their preparation and pharmaceutical compositions containing them
ATE269329T1 (de) Neue basische derivate von benz(e)isoindol-1-onen und pyrrolo(3,4-c)chinolin-1-onen mit 5-ht3- antagonistischer aktivität, ihre herstellung und ihre therapeutische verwendung
HK1018782A1 (en) 2,3-benzodiazepine derivatives their preparation as well as the intermediates and their use as medicaments
NZ212669A (en) Pyrazolo(3,4-d)pyridin-3-one derivatives,and pharmaceutical compositions containing such
AU4583489A (en) New indole derivatives, process for preparing them and pharmaceutical compositions containing them
ES8506716A1 (es) Un metodo de preparar espiro (indolo (1, 7-ab) (1, 5)-benzodiazepin-2, 4'-piperidinas)
YU44954B (en) Process for obtaining new tetracyclic derivatives of indole
PT86184A (en) Process for preparing cycloalka]b"pyrazolo]3,4-d"pyridin-3-one derivatives
ES2097093A1 (es) Nuevos compuestos derivados de 5h-tiazolo (3,2-a) pirimidin-5-ona.

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: N.V. ORGANON, NL

Free format text: FORMER OWNER(S): AKZO NOBEL NV, NL

FD9A Lapse of provisional protection due to non-payment of fees